What is the price target for IMRX stock?
12 analysts have analysed IMRX and the average price target is 17.17 USD. This implies a price increase of 250.41% is expected in the next year compared to the current price of 4.9.
IMMUNEERING CORP - CLASS A (IMRX) Forecast, Price Target & Analyst Ratings
NASDAQ:IMRX • US45254E1073
Current stock price
4.9 USD
+0.04 (+0.82%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IMMUNEERING CORP - CLASS A (IMRX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.30
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$17.17
Upside
+ 250.41%
From current price of $4.90 to mean target of $17.17, Based on 12 analyst forecasts
Low
$11.11
Median
$14.28
High
$31.50
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for IMRX. The average price target is 17.17 USD. This implies a price increase of 250.41% is expected in the next year compared to the current price of 4.9.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
IMRX was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IMRX.
In the previous month the buy percentage consensus was at a similar level.
IMRX was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Needham | Reiterate | Buy -> Buy |
| 2025-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-31 | Leerink Partners | Initiate | Outperform |
| 2025-09-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-26 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-25 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-15 | Needham | Maintains | Buy -> Buy |
| 2025-08-26 | Needham | Reiterate | Buy -> Buy |
| 2025-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-18 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-06-18 | Needham | Reiterate | Buy -> Buy |
| 2025-06-05 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-03-24 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-21 | Needham | Reiterate | Buy -> Buy |
| 2025-02-06 | Needham | Reiterate | Buy -> Buy |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2025-01-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-07 | Needham | Reiterate | Buy -> Buy |
| 2024-11-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | Needham | Reiterate | Buy -> Buy |
| 2024-09-13 | Needham | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.30
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 28.96%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
16.43%
EPS (3 Months)
16.43%
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.31M 20.31% | 2.08M -9.96% | 320K -84.62% | -100.00% | 24.48M | 45.191M 84.60% | 133.63M 195.70% | 228.78M 71.20% | 290.04M 26.78% | 399.65M 37.79% | 540.51M 35.25% | ||||
| EBITDA YoY % growth | -17.06M -171.66% | -33.84M -98.36% | -51.46M -52.07% | -59.355M -12.83% | -66.372M -9.57% | -79.028M -24.23% | -89.405M -13.13% | -133.518M -49.34% | -168.606M -26.28% | -177.48M -5.26% | -121.89M 31.32% | 4.59M 103.77% | 224.6M 4,793.25% | N/A | |
| EBIT YoY % growth | -17.08M -171.11% | -33.89M -98.42% | -51.74M -52.67% | -58.458M -12.90% | -65.416M -9.56% | -68.597M -7.18% | -96.047M -40.02% | -108.674M -13.15% | -91.113M 16.16% | -47.019M 48.39% | -7.322M 84.43% | -7.402M -1.08% | 110.74M 1,596.16% | 231.29M 108.86% | |
| Operating Margin | -739.39% | -1,629.33% | -16,168.75% | N/A | N/A | N/A | N/A | -443.93% | -201.62% | -35.19% | -3.20% | -2.55% | 27.71% | 42.79% | |
| EPS YoY % growth | N/A | N/A | -1.92 43.61% | -1.88 1.56% | -1.91 -7.41% | -1.45 32.02% | -1.41 -1.94% | -1.68 -19.51% | -1.45 13.48% | -1.13 22.39% | -0.59 47.89% | -0.44 25.44% | 1.54 451.16% | 3.59 133.11% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 28.96% | -0.38 5.65% | -0.40 -4.68% | -0.46 -155.00% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.842M -34.60% | -25.915M -75.60% | -27.343M -77.78% | -31.117M -126.26% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-1.77%
EPS Next 5 Year
9.49%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-26.85%
EBIT Next 5 Year
-22.09%
IMMUNEERING CORP - CLASS A / IMRX Forecast FAQ
What are the consensus estimates for IMRX stock next earnings?
The consensus EPS estimate for the next earnings of IMMUNEERING CORP - CLASS A (IMRX) is -0.3 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed IMMUNEERING CORP - CLASS A (IMRX)?
The number of analysts covering IMMUNEERING CORP - CLASS A (IMRX) is 12.